Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$92.49 +3.81%

+$3.89 today

Market cap
$6.04B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.50M

Average 0.95M

MIRM Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity turns negative

Q2 FY2026 total equity was -$10.42M, compared with $255.16M a year earlier. Over 3 fiscal years it compounded at +30.4% a year.

Context

  • Total equity amounted to 1.0% of total assets at the end of Q2 FY2026, down 34.2 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -104.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$10.42M-104.3% QoQ
Last fiscal yearDec 2025
$314.69M+39.5% YoY
Year agoJun 2025
$255.16M-104.1% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-104.1%——
1 year+39.5%——
3-year CAGR+30.4%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
314.69M USD
Year-over-year change
+39.5%
4-year CAGR
+27.2%

Total Equity vs competitors

How MIRM compares with its peers on the latest reported figures

  • MIRM's Jun 2026 total equity of -$10.42M is the 7th highest of the 8 companies compared; the peer median is $191.36M.
  • Its year-over-year change of -104.1% is the 7th highest of 8, against a peer median of -24.4%.
  • Total equity amounts to 1.0% of total assets for MIRM, versus a peer median of 42.1%.
MIRM Competitors Peer median
Total Equity for MIRM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AGIOAgios Pharmaceuticals, Inc.Mar 2026$1.11B -24.4%+2.7%93.6%
MDGLMadrigal Pharmaceuticals, Inc.Jun 2026$523.72M -24.7%+45.1%42.1%
ALTAltimmune, Inc.Mar 2026$283.99M +99.8%+6.7%84.6%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$191.36M -18.1%-7.5%78.0%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$116.59M +24.6%-41.4%37.0%
TVTXTravere Therapeutics, Inc.Sep 2026$22.58M -69.3%+38.9%2.7%
MIRMMirum Pharmaceuticals, Inc.Jun 2026-$10.42M -104.1%+30.4%1.0%
RAREUltragenyx Pharmaceutical Inc.Mar 2026-$229M -251.4%—17.7%
Peer median (excluding MIRM) $191.36M-24.4%+4.7%42.1%

Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents31.34M28M286.33M222.5M296.68M
Short-term Investments125.2M123.72M057.81M86.64M
Net Receivables4.37M23.99M67.97M78.29M123.33M
Inventory1.51M5.57M22.31M22.4M24.89M
Other Current Assets4.17M8.95M10.94M11.78M18.14M
Total Current Assets166.59M190.23M387.54M392.79M549.68M
Property, Plant & Equipment (Net)2.55M2.35M1.99M9.81M10.6M
Goodwill00000
Intangible Assets18.74M58.95M252.93M249.82M260.92M
Long-term Investments4.98M0012.53M8.11M
Tax Assets00000
Other Non-current Assets101.79M101.38M4.17M5.81M13.5M
Total Non-current Assets128.06M162.68M259.08M277.97M293.13M
Total Assets294.65M352.91M646.62M670.75M842.81M
Account Payables9.17M8.69M7.42M14.62M9.61M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities11.98M15.75M20.94M32.25M47.28M
Total Current Liabilities42.6M64.73M87.06M126.55M205.8M
Long-term Debt00306.42M308.08M309.8M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)129.92M140.35M000
Other Non-current Liabilities17K4.53M3.85M2.51M5.01M
Total Non-current Liabilities131.84M146.14M310.89M318.56M322.32M
Total Liabilities174.44M210.87M397.95M445.11M528.12M
Common Stock3K4K5K5K5K
Retained Earnings(257.16M)(392.82M)(556.24M)(644.18M)(667.54M)
Accumulated OCI(35K)(217K)1.64M(373K)351K
Other Stockholders Equity00000
Minority Interest00000
Total Equity120.21M142.04M248.67M225.64M314.69M
Total Debt2.61M2.19M308.14M317.76M319.45M
Net Debt(28.73M)(25.82M)21.82M95.26M22.77M

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Intrinsic Alpha fair value

Locked

Current Price

$92.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.